Started providing the article search AI system "Amanogawa" to educational and research institutions such as FRONTEO and universities.

Home » corporate » News » 2020 » Started providing the article search AI system "Amanogawa" to educational and research institutions such as FRONTEO and universities.
2020.08.03 Press release

--To the press -

Started providing the article search AI system "Amanogawa" to educational and research institutions such as FRONTEO and universities.

FRONTEO Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Mothers)

FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereafter FRONTEO) announced the academic plan of the paper search AI system "Amanogawa" and started providing it to educational and research institutions such as universities. To do.

 

Paper search AI system "Amanogawa" is PubMed※ 1And Open Targets※ 2It is a system that allows you to visually search not only those with matching keywords but also those that are conceptually close to each other from the latest treatise data contained in.When a researcher enters his or her hypothesis or keyword into "Amanogawa", the hypothesis and the latest papers related to the hypothesis are plotted on a map as location information, and the papers to be referred to can be visually extracted.

 

"Amanogawa" paper search screen.Each point shows a treatise.

 

FRONTEO has released this system to pharmaceutical companies, but with the announcement of this academic plan, the same function can be used at research institutes such as universities.In addition to drug discovery research, educational and research institutes a) look up peripheral information to write papers, b) search for the optimal treatment for the patient's symptoms, c) past cases related to difficult-to-diagnose symptoms. There are opportunities to search for articles in various situations, such as searching, d) acquiring the latest knowledge in specialized fields, but doctors can efficiently refer to articles in a short amount of time while engaging in medical work in the ward or outpatient department. I have to do it. "Amanogawa" can analyze and visualize the number of treatise information that is almost impossible for humans to read in just one day, which can greatly streamline the search for treatises at such educational and research institutions. ..

 

FRONTEO believes that the fusion of our artificial intelligence technology and cutting-edge medical research at educational and research institutes will lead to the creation of innovative ideas that cannot be considered with existing methods.

 

* 1 PubMed: A database that allows you to search for biological and medical treatises. Created by NCBI (National Center for Biotechnology Information) in NLM (National Library of Medicine).
* 2 Open Targets: Database for discovering drug discovery targets through public-private partnerships

 

Amanogawaabout URL: https://lifescience.fronteo.com/aidiscovery/amanogawa/

"Amanogawa (trademark / patent pending)" is FRONTEO's original AI engine "Concept Encoder (registered trademark: concept encoder)"®, Reading: Concept encoder) ”is a paper search AI system. All the papers existing in the latest databases of PubMed and Open Targets are converted into position information by "Concept Encoder", and when researchers enter their hypotheses and keywords, the latest papers related to the hypotheses and hypotheses are used as position information. Plot like a map. Since "Concept Encoder" analyzes the similarity of the contents of the articles and determines the position on the MAP, the contents of the articles can be specified by the displayed area, or the search can be narrowed down by dragging and dropping on the MAP. It enables visual search for treatises.

 

concept encoderabout URL: https://lifescience.fronteo.com/technology/conceptencoder/

"Concept Encoder (registered trademark: conceptencoder®, reading: concept encoder)" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. "Concept Encoder" can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

 

FRONTEOabout URL: https://www.fronteo.com/

FRONTEO is an in-house developed AI engine "KIBIT" that specializes in natural language processing.®"And" concept encoder®Is a data analysis company that supports the business of a company by extracting meaningful and important information from a huge amount of text data using. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic evidence disclosure)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we will expand the business field to the life science field and business intelligence field from 8, and use AI to "turn text data into knowledge" to support drug discovery. , Dementia diagnosis support, financial, personnel, sales support, etc., contributing to solving various corporate issues. Listed on TSE Mothers on June 2014, 2007.The capital is 6 thousand yen (as of March 26, 2,568,651).

 

<Contact information for the press>
Public Relations Officer, FRONTEO Inc. Segawa
Email: pr_contact@fronteo.com

<Inquiries about Life Science AI Business>
Life Science AI Business Department, FRONTEO, Inc.
https://lifescience.fronteo.com/contact